Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases

Imagem de Miniatura
Arquivos
art_CASADIO_Lipase_and_factor_V_but_not_viral_load_2019.PDF (539.6 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUNDACO OSWALDO CRUZ
Autores
Citação
MEMORIAS DO INSTITUTO OSWALDO CRUZ, v.114, article ID UNSP e190033, 8p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND Despite a highly efficacious vaccine, yellow fever (YF) is still a major threat in developing countries and a cause of outbreaks. In 2018, the Brazilian state of Sao Paulo witnessed a new YF outbreak in areas where the virus has not been detected before. OBJECTIVE The aim is to describe the clinical and laboratorial characteristics of severe cases of YF, evaluate viral to determine markers associated with fatal outcome. METHODS Acute severe YF cases (n = 62) were admitted to the Intensive Care Unit of a reference hospital and submitted to routine laboratorial evaluation on admission. YFV-RNA was detected in serum and urine by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and then sequenced. Patients were classified in two groups: survival or death. FINDINGS In the univariate analysis the following variables were associated with outcome: alanin aminotransferase (ALT), aspartat aminotransferase (AST), AST/ALT ratio, total bilirubin (TB), chronic kidney disease epidemiology collaboration (CKD-EPI), ammonia, lipase, factor V, international normalised ratio (INR), lactate and bicarbonate. Logistic regression model showed two independent variables associated with death: lipase [odds ratio (OR) 1.018, 95% confidence interval (CI) 1.007 to 1.030, p = 0.002], and factor V (OR -0.955, 95% CI 0.929 to 0.982, p = 0.001). The estimated lipase and factor V cut-off values that maximised sensitivity and specificity for death prediction were 147.5 U/L [area under the curve (AUC) = 0.879], and 56.5% (AUC = 0.913). MAIN CONCLUSIONS YF acute severe cases show a generalised involvement of different organs (liver, spleen, heart, kidneys, intestines and pancreas), and different parameters were related to outcome. Factor V and lipase are independent variables associated with death, reinforcing the importance of hemorrhagic events due to fulminant liver failure and pointing to pancreatitis as a relevant event in the outcome of the disease.
Palavras-chave
yellow fever, lipase, factor v, viral load
URI
https://observatorio.fm.usp.br/handle/OPI/32482
Referências
  1. Ahmed QA, 2017, TROP DOCT, V47, P92, DOI 10.1177/0049475517699726
  2. Bae HG, 2005, J CLIN VIROL, V33, P274, DOI 10.1016/j.jcv.2004.12.001
  3. Barbosa CM, 2018, EMERG INFECT DIS, V24, P176, DOI 10.3201/eid2401.171310
  4. Barrett Alan D, 2003, Adv Virus Res, V61, P291, DOI 10.1016/S0065-3527(03)61007-9
  5. Buber Jonathan, 2008, Travel Med Infect Dis, V6, P373, DOI 10.1016/j.tmaid.2008.08.001
  6. Chen Z, 2016, EMERG MICROBES INFEC, V5, P1
  7. Clements AN, 2017, J VECTOR ECOL, V42, P208, DOI 10.1111/jvec.12261
  8. Fernandes NCCD, 2017, EMERG INFECT DIS, V23, P2038, DOI 10.3201/eid2312.170685
  9. Domingo C, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0128-8
  10. Domingo C, 2012, J CLIN MICROBIOL, V50, P4054, DOI 10.1128/JCM.01799-12
  11. Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
  12. Governo do Estado de Sao Paulo/SES/CCD/CVE/DDTVZ-Secretaria de Estado da Saude/Coordenadoria de Controle de Doencas/Centro de Vigilancia Epidemiologica/Divisao de Doencas Transmitidas por Vetores e Zoonoses, 2019, B EPIDEMIOLOGICO FEB
  13. Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI 10.1021/BK-1999-0734.CH008
  14. HARRISON AK, 1980, EXP MOL PATHOL, V32, P102, DOI 10.1016/0014-4800(80)90047-7
  15. Jain V, 2014, J GLOB INFECT DIS, V6, P76, DOI 10.4103/0974-777X.132050
  16. Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291
  17. Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI 10.1016/S1473-3099(16)30513-8
  18. Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI 10.1093/molbev/msw054
  19. Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
  20. Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
  21. Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
  22. Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
  23. Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
  24. MONATH TP, 1987, REV INFECT DIS, V9, P165
  25. MS-Ministerio da Saude, 2017, MON PER SAZ FEBR AM
  26. Nassar E da S, 1995, Rev Inst Med Trop Sao Paulo, V37, P337
  27. Nunes MRT, 2011, J VIROL METHODS, V174, P29, DOI 10.1016/j.jviromet.2011.02.025
  28. Oliveira F., 1969, HIST FEBRE AMARELA B
  29. PERELMAN A, 1974, AM J TROP MED HYG, V23, P1150, DOI 10.4269/ajtmh.1974.23.1150
  30. Possas C, 2018, MEM I OSWALDO CRUZ, V113, P1, DOI 10.1590/0074-02760170361
  31. Reusken CBEM, 2017, J CLIN MICROBIOL, V55, P3294, DOI 10.1128/JCM.01113-17
  32. Rogers DJ, 2006, ADV PARASIT, V62, P181, DOI 10.1016/S0065-308X(05)62006-4
  33. Seetharam P, 2010, EURASIAN J MED, V42, P151, DOI 10.5152/eajm.2010.41
  34. Tesh RB, 2001, J INFECT DIS, V183, P1431, DOI 10.1086/320199
  35. Vicenzi E, 2018, BIOCHEM SOC T, V46, P609, DOI [10.1042/BST20170399, 10.1042/bst20170399]
  36. Xiao SY, 2001, J INFECT DIS, V183, P1437, DOI 10.1086/320200

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/01
Carregar mais